• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Smith Ernest S. (Amendment)

    5/14/24 4:36:35 PM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VCNX alert in real time by email
    SEC FORM 4/A SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Smith Ernest S.

    (Last) (First) (Middle)
    C/O VACCINEX, INC.
    1895 MOUNT HOPE AVENUE

    (Street)
    ROCHESTER NY 14620

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    VACCINEX, INC. [ VCNX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    SVP, Research & CSO
    3. Date of Earliest Transaction (Month/Day/Year)
    03/21/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    03/22/2024
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $8.21(1) 03/21/2024(1) A 1,341 (2) 03/21/2034 Common Stock 1,341 $0 1,341 D
    Explanation of Responses:
    1. Due to an administrative error, the original Form 4 mistakenly listed the transaction date as March 20, 2024. The transaction actually occurred on March 21, 2024. Accordingly, the exercise price of the stock option is $8.21 per share, as opposed to the exercise price of $8.32 that was listed in the original Form 4.
    2. This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 21, 2024 grant date.
    /s/ Maurice Zauderer, Attorney-in-Fact for Ernest S. Smith 05/14/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VCNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VCNX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VCNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

      Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. Pepinemab, Semaphorin 4D blocking immunotherapy, also appears to induce the formation of efficient lymphoid structures in "cold" tumors of patients with recurrent and metastatic head and neck cancer. ROCHESTER, N.Y., April 21, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer's disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present exciting ne

      4/21/25 8:45:00 AM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

      ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC:VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market ("Nasdaq") of its decision to delist the Company's shares of common stock, par value $0.0001 per share (the "Common Stock"), from Nasdaq. Trading in the Common Stock on Nasdaq has been suspended since December 18, 2024. Vaccinex intends to file a Form 25 with the Securities and Exchange Commission on or about March 17, 2025 to

      3/7/25 5:15:00 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaccinex Announces Receipt of Delisting Notification from Nasdaq

      ROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that on December 16, 2024, the Company received written notice (the "Notice") from the Office of General Counsel of The Nasdaq Stock Market ("Nasdaq") indicating that the Nasdaq Hearings Panel has determined to delist the Company's shares from Nasdaq due to the Company's failure to meet Nasdaq's continued listing standards. As previously disclosed, the Company has not been

      12/17/24 9:00:00 AM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VCNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $VCNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $VCNX
    SEC Filings

    See more
    • Amendment: SEC Form SC 13D/A filed by Vaccinex Inc.

      SC 13D/A - VACCINEX, INC. (0001205922) (Subject)

      11/18/24 4:15:28 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Vaccinex Inc.

      SC 13G - VACCINEX, INC. (0001205922) (Subject)

      11/14/24 3:39:20 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Vaccinex Inc.

      SC 13D/A - VACCINEX, INC. (0001205922) (Subject)

      9/20/24 5:15:25 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Friedberg Albert bought $451 worth of shares (100 units at $4.51) (SEC Form 4)

      4 - VACCINEX, INC. (0001205922) (Issuer)

      8/13/24 4:30:45 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Friedberg Albert bought $30,349 worth of shares (6,406 units at $4.74) (SEC Form 4)

      4 - VACCINEX, INC. (0001205922) (Issuer)

      8/7/24 4:04:52 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Friedberg Albert bought $55,238 worth of shares (11,703 units at $4.72) (SEC Form 4)

      4 - VACCINEX, INC. (0001205922) (Issuer)

      8/2/24 4:05:32 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Vaccinex Inc.

      10-K - VACCINEX, INC. (0001205922) (Filer)

      4/15/25 5:12:41 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-K filed by Vaccinex Inc.

      NT 10-K - VACCINEX, INC. (0001205922) (Filer)

      4/1/25 7:01:02 AM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Vaccinex Inc.

      15-12G - VACCINEX, INC. (0001205922) (Filer)

      3/27/25 8:24:58 AM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VCNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Friedberg Albert was granted 30,756 shares (SEC Form 4)

      4 - VACCINEX, INC. (0001205922) (Issuer)

      11/18/24 4:06:19 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Zauderer Maurice was granted 46,153 shares (SEC Form 4)

      4 - VACCINEX, INC. (0001205922) (Issuer)

      11/18/24 4:05:50 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Zauderer Maurice exercised 113,650 shares at a strike of $5.64 (SEC Form 4)

      4 - VACCINEX, INC. (0001205922) (Issuer)

      9/20/24 4:14:02 PM ET
      $VCNX
      Biotechnology: Pharmaceutical Preparations
      Health Care